Exelixis Access Services® (EASE)

EASE complements your practice's services with options to help your patients afford and obtain their medicine.

image
CALL: 1-844-900-EASE
(1-844-900-3273)
image
Monday to Friday,
8:00 AM to 8:00 PM ET
Dosing

Exelixis Access Services® (EASE) enrollment, including co-pay and Patient Assistance Program (PAP)

Download the form
Dosing

To obtain patient consent for enrollment in EASE programs

Download the form
Dosing

EASE Co-Pay Program

Enroll eligible patients
Dosing

Support your patients who may require a dose reduction

Download the form

HELP PATIENTS START AND STAY ON CABOMETYX® (cabozantinib)

image
CABOMETYX Quick Start Program*—Newly prescribed patients who experience an insurance coverage decision delay of 5 days or more can receive their therapy sooner. Additional restrictions and eligibility rules apply.
image
Dose Exchange Program—Patients who require a dose reduction can receive a onetime free supply to help them transition to a lower dose. Additional restrictions and eligibility rules apply.

DETERMINE ELIGIBILITY FOR PATIENT FINANCIAL ASSISTANCE

image
EASE Co-pay Program—Commercial patients who cannot afford their co-pay may be able to lower it to no more than $10 per month. Additional restrictions and eligibility rules apply.
  • Self-dispensing practices can apply online on behalf of patients here or direct their patient to CABOMETYX.com to enroll themselves. If using the EASE Enrollment Form, please check the box in Section 1 and have the patient fill out the Patient Authorization Form here or from your Exelixis Oncology Account Manager.
image
EASE Patient Assistance Program (PAP)—Patients who cannot afford their drug costs may be able to receive CABOMETYX free of charge. Additional restrictions and eligibility rules apply.

SUPPORT COVERAGE DETERMINATION

Benefits investigation—EASE can verify the patient’s coverage for CABOMETYX with his or her health insurance plan.

Prior authorization (PA) assistance—EASE can identify the health insurance plan’s PA requirements, including specialist prescribing requirements, for obtaining approval to prescribe CABOMETYX.

Appeals support and follow-up—Our appeals specialists can help you identify the next steps to have the denial reviewed by the insurance plan’s appeal review committee and, if necessary, an independent third party.

This description of the Exelixis® Access Services program is for informational purposes only. Exelixis makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.

*Limited to the following ICD-10-CM diagnoses: C64, C64.1, C64.2, and C64.9. Additional restrictions may apply.

 

INDICATION

CABOMETYX® (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Severe and fatal hemorrhages have occurred with CABOMETYX. In RCC trials, the incidence of Grade ≥3 hemorrhagic events was 3% in CABOMETYX patients. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.

Gastrointestinal (GI) Perforations and Fistulas: In RCC trials, GI perforations were reported in 1% of CABOMETYX patients. Fatal perforations occurred in patients treated with CABOMETYX. In RCC studies, fistulas were reported in 1% of CABOMETYX patients. Monitor patients for symptoms of perforations and fistulas, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a GI perforation or a fistula that cannot be appropriately managed.

Thrombotic Events: Thrombotic events increased with CABOMETYX. In RCC trials, venous thromboembolism occurred in 9% (including 5% pulmonary embolism) and arterial thromboembolism occurred in 1% of CABOMETYX patients. Fatal thrombotic events occurred in the cabozantinib clinical program. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.

Hypertension and Hypertensive Crisis: Treatment-emergent hypertension, including hypertensive crisis, increased with CABOMETYX. In RCC trials, hypertension was reported in 44% (18% Grade ≥3) of CABOMETYX patients. Monitor blood pressure prior to initiation and regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX if there is evidence of hypertensive crisis or for severe hypertension that cannot be controlled with antihypertensive therapy or medical management.

Diarrhea: In RCC trials, diarrhea occurred in 74% of CABOMETYX patients. Grade 3 diarrhea occurred in 11% of CABOMETYX patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal treatments until improvement to Grade 1; resume CABOMETYX at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): In RCC trials, PPE occurred in 42% of CABOMETYX patients. Grade 3 PPE occurred in 8% of CABOMETYX patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 PPE or Grade 3 PPE until improvement to Grade 1; resume CABOMETYX at a reduced dose.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib clinical program. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Embryo-fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during CABOMETYX treatment and for 4 months after the last dose.

ADVERSE REACTIONS

The most commonly reported (≥25%) adverse reactions were: diarrhea, fatigue, nausea, decreased appetite, hypertension, PPE, weight decreased, vomiting, dysgeusia, and stomatitis.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage.

Strong CYP3A4 Inducers: If concomitant use with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed while taking CABOMETYX and for 4 months after the final dose.

Hepatic Impairment: In patients with mild to moderate hepatic impairment, reduce the CABOMETYX dosage. CABOMETYX is not recommended for use in patients with severe hepatic impairment.

Please see accompanying full Prescribing Information.